ArticleCancer imaging : the official publication of the International Cancer Imaging Society2026
Prognostic value of PSMA PET-derived tumor volume in metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide.
Article in Cancer imaging : the official publication of the International Cancer Imaging Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn metastatic castration-resistant prostate cancer (mCRPC), clinical outcomes remain highly heterogeneous despite the widespread use of next-generation androgen receptor pathway inhibitors. Reliable imaging-based biomarkers capable of reflecting whole-body tumor burden and predicting prognosis are needed. Prostate-specific membrane antigen (PSMA) PET-derived volumetric parameters have emerged as potential prognostic tools, yet their role in patients treated with abiraterone or enzalutamide remains insufficiently defined.
methodsWe retrospectively analyzed 54 patients with mCRPC treated with abiraterone or enzalutamide between 2013 and 2025. Baseline 68Ga-PSMA PET/CT scans were used to derive quantitative imaging parameters, including PSMA tumor volume (PSMA-TV), total lesion PSMA expression (PSMA-TL), and SUV-based metrics. Overall survival (OS) and progression-free survival (PFS) were assessed using Kaplan-Meier analyses. Receiver operating characteristic analyses identified optimal cut-off values, and Cox proportional hazards models were used to determine independent prognostic factors.
resultsHigher baseline PSMA-TV and PSMA-TL were significantly associated with inferior OS and PFS. A PSMA-TV cut-off of ≥ 44.84 demonstrated good discriminatory ability for mortality prediction (AUC = 0.707, p = 0.010). In multivariate analysis, PSMA-TV ≥ 44.84 emerged as an independent predictor of mortality (HR 9.48, 95% CI 1.14-78.97; p = 0.037). Early PSA kinetics provided complementary prognostic information, and a PSA level ≥ 0.20 ng/mL at 6 months was independently associated with disease progression.
conclusionPSMA PET-derived volumetric parameters, particularly PSMA tumor volume, provide robust prognostic information in mCRPC patients treated with abiraterone or enzalutamide. When combined with early PSA kinetics, these imaging biomarkers enable improved risk stratification and may support more individualized treatment strategies. Prospective multicenter studies are warranted to validate these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.